DADaniel Almaguer-Morales

Daniel Almaguer-Morales

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel Almaguer-Morales has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    P-18 PREVALENCE AND EPIDEMIOLOGICAL CHARACTERISTICS OF INFECTIONS IN PATIENTS WITH CHRONIC LIVER DISEASE: RETROSPECTIVE ANALYSIS FROM A GENERAL HOSPITAL IN MONTERREY, NUEVO LEON, MEXICO

    by José Alfredo Salinas-Casanova, Daniel Almaguer-Morales, Salvador Bruno Valdovinos-Chávez, Luis Alonso Morales-Garza, María Teresa Sánchez-Ávila, Juan Francisco Sánchez-Ávila

  • Löfgren Syndrome with Hypercalcemia and Neuroendocrinological Involvement: A Case Report

    by Daniel Almaguer-Morales, David Eugenio Hinojosa-González, Alejandro Garza-Alpirez

    Background: Sarcoidosis is a systemic inflammatory disease of unknown etiology that can affect virtually any organ. Löfgren syndrome, characterized by erythema nodosum, hilar lymphadenopathy, fever and polyarthritis, represents only 20-30% of the cases of sarcoidosis. Only 2- 10% of the cases feature hypercalcemia. Case: The case of a 42-year-old Hispanic woman with a history of erythema nodosum and three weeks of nausea, emesis, constipation, asthenia, adynamia, polydipsia, and somnolence, concomitant with hypercalcemia, but normal parathyroid hormone (PTH) and 25-hydroxyvitamin D has been presented. The initial diagnostic approach was based upon the suspicion of multiple myeloma or bone metastases; however, further findings of bilateral hilar lymphadenopathy, elevated serum angiotensin-converting enzyme (ACE) and a right inguinal lymphadenomegaly suggested an alternate diagnosis. Biopsy of the latter supported sarcoidosis as the diagnosis. She was successfully treated in the hospital with zoledronic acid and as an outpatient with immunosuppressive therapy. Persistence of a previously undisclosed symptom of oligomenorrhea led to the detection of hyperprolactinemia secondary to hypophyseal infiltration, refractory to immunosuppressive therapy but with an adequate response to cabergoline. Conclusion: This case strays from Löfgren Syndrome’s expected behavior, presenting a more progressive, multisystemic disease. This case report was written in adhThis case strays from Löfgren Syndrome’s expected behavior, presenting a more progressive, multisystemic disease. This case report was written in adherence to the CARE guidelines of 2013 to include information in it.erence to the CARE guidelines of 2013 to include information in it.